Radical Nephrectomy with or without Lymph Node Dissection for pT3 Renal Cell Carcinoma: A Propensity Score-based Analysis
Pin Li, Cheng Yun Peng, Liangyou Gu, Yongpeng Xie, Wenyuan Nie, Zhang Yu, Yundong Xuan, Donglai Shen, Songliang Du, Lu Tang, Yuanxin Yao, Fan Yang, Xin Ma, Xu Zhang · Journal of Cancer · 2019
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2019
Abstract
Objectives: To study whether radical nephrectomy (RN) with lymph node dissection (LND) can benefit pT3 renal cell carcinoma (RCC) patients versus no LND under the 2018 American Joint Committee on Cancer TNM classification system.Subjects/Patients and Methods: We performed a retrospective cohort study of clinicopathological data for 245 T3 RCC patients, who underwent radical nephrectomy between January 2006 and December 2013 at our center, including 67 (27.1%) who underwent LND.The relationships between the LND and progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) were evaluated using 1:1 propensity score (PS) matching.Then, Kaplan-Meier survival analysis and Cox regression analysis were conducted to study whether these patients can benefit from LND.
Depending on the LND number, we divided the cohort into two groups for further comparation.At last, we validated the results with the TCGA database KIRC patients.Results: The median follow-up time was 4.9 years.Sixty-seven pairs of patients were screened by the PS and were further analyzed.We conducted a Cox regression with the survival data and found that the LND group, compared with the non-LND group, showed no survival benefit on PFS, CSS, and OS (p = 0.444, 0.809, and 0.816, respectively).However, the removal of 5 or more LNs showed negative effect on OS (p = 0.0387).TCGA cohort results are mostly consistent with our findings.Conclusion: RN with LND cannot improve the PFS, CSS, or OS for pT3 renal cell carcinoma patients.
Open the resolved locator · 10.7150/jca.30375
Metadata licence: OpenAlex metadata (CC0)